This webinar reviews the use and application of an at home urinary test that measures the presence of progesterone in urine (or more specifically tests a urine metabolite of progesterone, pregnanediol 3-glucuronide (PdG), and how this can be used alongside Fertility awareness based methods and may aid some users in increasing the efficacy of Fertility Awareness Based Methods. Dr. Martin Owen is a fellow of the Reproductive Health Research Institute (RHRI) and founded Vitae Medical Solutions to address the need for clinical and technological solutions in the Restorative Reproductive Medicine field internationally.
Recordings from IIRRM’s AGM and International Conference for RRM held in Dublin and Restorative Reproduction hosted by NeoFertility are now available for purchase. Updates in progesterone, DHEA and the Oestradiol curve, immunological aspects of infertility and reproductive health, treatment of silent endometriosis, an overview of the new Neo app and case studies as well as some surprising discoveries! Fill out the online evaluations for each day to receive up to 12 CME/CPD are available until Sept 27, 2019.
There is no excerpt because this is a protected post.
Presented by Joseph Stanford, MD, MSPH. Review the concepts of pregnancy rates, effectiveness, perfect use, typical use, achieving-related behavior, and avoiding-related behavior, in relation to natural family planning, fertility awareness, and fertility appreciation methods. Discuss statistical methods for effectiveness studies and examine strengths and weaknesses of existing studies.
First Name * Last Name * Titles & Degrees Headshot This will be used in promoting the webinar. Please enter your CV or a short […]
The Neo Fertility Conference is being recorded for those that are unable to attend the conference on Friday and to provide future education for […]
Dr. Robert Chasuk is the Associate Director of the Family Medicine Residency Program at the Baton Rouge General Medical Center, in LA, USA, where he […]
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age (6.8%–18%), is among the most common causes of infertility due to ovulation factors, and accounts for 55%–70% of infertility cases caused by chronic anovulation. In this study, we used a combination of letrozole and clomiphene in patients resistant to both drugs individually, and studied the effects of this combination in ovulation and pregnancy in resistant PCOS patients.